ArticleMycopathologia2025
Direct Identification of Yeasts from Blood Cultures and Body Fluids Using MALDI-TOF MS with Concurrent Antifungal Susceptibility Testing.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising incidence of invasive fungal infections has been accompanied by an increasing prevalence of antifungal resistance among fungal pathogens. Rapid identification of causative agents and their antifungal susceptibility profiles is critical for initiating timely, species-specific targeted therapy. In this context, we evaluated a MALDI-TOF MS-based method for the rapid identification of clinically relevant yeast species directly from blood cultures and body fluids, coupled with direct antifungal susceptibility testing (Direct-AFST). Our study evaluated over 700 yeast isolates, encompassing diverse Candida and non-Candida species, using MALDI-TOF MS. Additionally, antifungal susceptibility was assessed for 250 isolates, demonstrating excellent categorical agreement between Direct-AFST and conventional culture-based AFST (Culture-AFST). Our findings highlight the clinical utility of MALDI-TOF MS for accurate and rapid yeast identification directly from positive blood cultures, irrespective of microbial load or sample preparation method. Furthermore, the successful application of Direct-AFST underscores its potential for early detection of antifungal resistance, significantly reducing diagnostic turnaround times and improving patient management.
Indexed as
Identifiers
40854990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.